XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.23.3

Non-marketable Securities | 9 Months Ended
--- | ---
Sep. 30, 2023
Non-marketable Securities |
Non-marketable Securities | Note 4 Non-marketable Securities ​ The carrying balance of non-marketable securities are summarized as follows as of the dates indicated: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2023 | ​ | December 31, 2022
Federal Reserve Bank stock | ​ | $ | 24,062 | ​ | $ | 18,096
Federal Home Loan Bank stock | ​ | ​ | 14,787 | ​ | ​ | 20,294
Equity method investments | ​ | ​ | 23,968 | ​ | ​ | 21,659
Convertible preferred stock | ​ | ​ | 25,000 | ​ | ​ | 29,000
Total | ​ | $ | 87,817 | ​ | $ | 89,049
​ Non-marketable securities included FRB stock, FHLB stock and other non-marketable securities. During the nine months ended September 30, 2023 and 2022, purchases of non-marketable securities, consisting primarily of FHLB stock, totaled $93.9 million and proceeds of non-marketable securities, consisting of redemptions of FHLB stock, totaled $90.3 million. The changes in the Company’s FHLB stock holdings are directly correlated to FHLB line of credit advances and paydowns. During the nine months ended September 30, 2022, purchases totaling $11.5 million were comprised of other non-marketable securities, and proceeds from other non-marketable securities totaled $0.1 million. ​ FRB and FHLB stock ​ At September 30, 2023 and December 31, 2022, the Company held FRB stock and FHLB stock for regulatory or debt facility purposes. These are restricted securities which, lacking a market, are carried at cost. There have been no identified events or changes in circumstances that may have an adverse effect on the FRB and FHLB stock carried at cost. ​ Other non-marketable securities ​ Other non-marketable securities consist of equity method investments and convertible preferred stock without a readily determinable fair value. During the nine months ended September 30, 2023, the Company recorded $4.0 million in impairments on convertible preferred stock related to venture capital investments, included in other non-interest income in the Company’s consolidated statements of operations. No impairments were recorded during 2022. During the three and nine months ended September 30, 2023, the Company recorded net unrealized losses on equity method investments totaling zero and $0.4 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded net unrealized gains on equity method investments totaling $1.3 million and $1.4 million, respectively. These gains and losses were recorded in other non-interest income in the Company’s consolidated statements of operations.

X
- Definition Disclosure - Non-Marketable Securities (Narrative) [Abstract] + References No definition available. + Details
Name: | nbhc_DisclosureNonMarketableSecuritiesNarrativeAbstract
Namespace Prefix: | nbhc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities And Nonmarketable Equity Investments [Text Block] + References No definition available. + Details
Name: | nbhc_SecuritiesAndNonmarketableEquityInvestmentsTextBlock
Namespace Prefix: | nbhc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration